Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results

2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.

Advertisement

Advertisement



Advertisement